Industries > Pharma > Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

PUBLISHED: 19 December 2018
PAGES: 160
PRODUCT CODE: PHA0349

Clear
WOOCS 2.2.1

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts– all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Asthma & COPD Therapies Market forecasts from 2019-2029

• Profiles of the leading 20 asthma & COPD companies:
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• GlaxoSmithKline
• Lallemand Pharma International
• Merck
• MundiPharma
• Novartis
• Pulmatrix
• Roche
• Sanofi/Regeneron
• Sunovion
• Teva
• Theravance Biopharma|Mylan Inc.
• Vectura Group plc
• Verona Pharma plc

Top 20 Asthma & COPD Companies 2019-2029

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast from 2019-2029
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


Latest Pharma news

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

READ

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

READ

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

READ

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

READ

Categories

Category